{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,3,12]],"date-time":"2023-03-12T05:14:01Z","timestamp":1678598041357},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2014,4,26]],"date-time":"2014-04-26T00:00:00Z","timestamp":1398470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2014,4,26]],"date-time":"2014-04-26T00:00:00Z","timestamp":1398470400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1007\/s10637-014-0104-7","type":"journal-article","created":{"date-parts":[[2014,4,25]],"date-time":"2014-04-25T02:08:01Z","timestamp":1398391681000},"page":"717-722","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Evaluation of a novel blood pressure scoring method and its association with clinical response in cancer patients treated with anti-vascular endothelial growth factor therapy"],"prefix":"10.1007","volume":"32","author":[{"given":"Mehmet Asim","family":"Bilen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Bernard","family":"Durand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lacey","family":"McQuinn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth R.","family":"Hess","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siqing","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerald S.","family":"Falchook","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David S.","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer J.","family":"Wheler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rabih","family":"Said","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael S.","family":"Ewer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Razelle","family":"Kurzrock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aung","family":"Naing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,4,26]]},"reference":[{"issue":"6","key":"104_CR1","first-page":"353","volume":"65","author":"E Ichihara","year":"2011","unstructured":"Ichihara E, Kiura K, Tanimoto M (2011) Targeting angiogenesis in cancer therapy. Acta Med Okayama 65(6):353\u2013362","journal-title":"Acta Med Okayama"},{"issue":"5","key":"104_CR2","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.yexcr.2005.11.015","volume":"312","author":"J Folkman","year":"2006","unstructured":"Folkman J (2006) Antiangiogenesis in cancer therapy\u2013endostatin and its mechanisms of action. Exp Cell Res 312(5):594\u2013607. doi:10.1016\/j.yexcr.2005.11.015","journal-title":"Exp Cell Res"},{"issue":"1","key":"104_CR3","first-page":"1","volume":"32","author":"AG Linkous","year":"2012","unstructured":"Linkous AG, Yazlovitskaya EM (2012) Novel therapeutic approaches for targeting tumor angiogenesis. Anticancer Res 32(1):1\u201312","journal-title":"Anticancer Res"},{"issue":"1","key":"104_CR4","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1200\/JCO.2003.10.066","volume":"21","author":"F Kabbinavar","year":"2003","unstructured":"Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, Bergsland E (2003) Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)\/leucovorin (LV) with FU\/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21(1):60\u201365","journal-title":"J Clin Oncol"},{"issue":"2","key":"104_CR5","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa060655","volume":"356","author":"B Escudier","year":"2007","unstructured":"Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356(2):125\u2013134. doi:10.1056\/NEJMoa060655","journal-title":"N Engl J Med"},{"issue":"2","key":"104_CR6","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJMoa065044","volume":"356","author":"RJ Motzer","year":"2007","unstructured":"Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356(2):115\u2013124. doi:10.1056\/NEJMoa065044","journal-title":"N Engl J Med"},{"issue":"8","key":"104_CR7","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/nrclinonc.2009.94","volume":"6","author":"HX Chen","year":"2009","unstructured":"Chen HX, Cleck JN (2009) Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 6(8):465\u2013477. doi:10.1038\/nrclinonc.2009.94","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"104_CR8","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S1470-2045(08)70003-2","volume":"9","author":"S Wu","year":"2008","unstructured":"Wu S, Chen JJ, Kudelka A, Lu J, Zhu X (2008) Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol 9(2):117\u2013123. doi:10.1016\/S1470-2045(08)70003-2","journal-title":"Lancet Oncol"},{"issue":"2","key":"104_CR9","doi-asserted-by":"publisher","first-page":"341","DOI":"10.2147\/tcrm.2007.3.2.341","volume":"3","author":"C Le Tourneau","year":"2007","unstructured":"Le Tourneau C, Raymond E, Faivre S (2007) Sunitinib: a novel tyrosine kinase inhibitor. A brief review of its therapeutic potential in the treatment of renal carcinoma and gastrointestinal stromal tumors (GIST). Ther Clin Risk Manag 3(2):341\u2013348","journal-title":"Ther Clin Risk Manag"},{"issue":"Suppl 1","key":"104_CR10","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1634\/theoncologist.9-suppl_1-36","volume":"9","author":"E Bergsland","year":"2004","unstructured":"Bergsland E, Dickler MN (2004) Maximizing the potential of bevacizumab in cancer treatment. Oncologist 9(Suppl 1):36\u201342","journal-title":"Oncologist"},{"issue":"28","key":"104_CR11","doi-asserted-by":"publisher","first-page":"11306","DOI":"10.1073\/pnas.1203275109","volume":"109","author":"SB Sunshine","year":"2012","unstructured":"Sunshine SB, Dallabrida SM, Durand E, Ismail NS, Bazinet L, Birsner AE, Sohn R, Ikeda S, Pu WT, Kulke MH, Javaherian K, Zurakowski D, Folkman JM, Rupnick M (2012) Endostatin lowers blood pressure via nitric oxide and prevents hypertension associated with VEGF inhibition. Proc Natl Acad Sci U S A 109(28):11306\u201311311. doi:10.1073\/pnas.1203275109","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"104_CR12","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1093\/annonc\/mdn637","volume":"20","author":"M Scartozzi","year":"2009","unstructured":"Scartozzi M, Galizia E, Chiorrini S, Giampieri R, Berardi R, Pierantoni C, Cascinu S (2009) Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol 20(2):227\u2013230. doi:10.1093\/annonc\/mdn637","journal-title":"Ann Oncol"},{"issue":"5","key":"104_CR13","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1007\/s00280-011-1604-1","volume":"68","author":"A De Stefano","year":"2011","unstructured":"De Stefano A, Carlomagno C, Pepe S, Bianco R, De Placido S (2011) Bevacizumab-related arterial hypertension as a predictive marker in metastatic colorectal cancer patients. Cancer Chemother Pharmacol 68(5):1207\u20131213. doi:10.1007\/s00280-011-1604-1","journal-title":"Cancer Chemother Pharmacol"},{"issue":"9","key":"104_CR14","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1093\/jnci\/djr128","volume":"103","author":"BI Rini","year":"2011","unstructured":"Rini BI, Cohen DP, Lu DR, Chen I, Hariharan S, Gore ME, Figlin RA, Baum MS, Motzer RJ (2011) Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 103(9):763\u2013773. doi:10.1093\/jnci\/djr128","journal-title":"J Natl Cancer Inst"},{"key":"104_CR15","unstructured":"Institute NC (2009) Common terminology criteria for adverse events v4.0 In Edition 2009"},{"issue":"10","key":"104_CR16","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1097\/00004872-200310000-00001","volume":"21","author":"R Cifkova","year":"2003","unstructured":"Cifkova R, Erdine S, Fagard R, Farsang C, Heagerty AM, Kiowski W, Kjeldsen S, Luscher T, Mallion JM, Mancia G, Poulter N, Rahn KH, Rodicio JL, Ruilope LM, van Zwieten P, Waeber B, Williams B, Zanchetti A (2003) Practice guidelines for primary care physicians: 2003 ESH\/ESC hypertension guidelines. J Hypertens 21(10):1779\u20131786. doi:10.1097\/01.hjh.0000084773.37215.1b","journal-title":"J Hypertens"},{"issue":"4","key":"104_CR17","first-page":"17","volume":"55","author":"ML Cuddy","year":"2005","unstructured":"Cuddy ML (2005) Treatment of hypertension: guidelines from JNC 7 (the seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure 1). J Pract Nurs 55(4):17\u201321, quiz 22\u201313","journal-title":"J Pract Nurs"},{"issue":"3","key":"104_CR18","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205\u2013216","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"104_CR19","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1634\/theoncologist.2010-0002","volume":"16","author":"O Mir","year":"2011","unstructured":"Mir O, Coriat R, Cabanes L, Ropert S, Billemont B, Alexandre J, Durand JP, Treluyer JM, Knebelmann B, Goldwasser F (2011) An observational study of bevacizumab-induced hypertension as a clinical biomarker of antitumor activity. Oncologist 16(9):1325\u20131332. doi:10.1634\/theoncologist.2010-0002","journal-title":"Oncologist"},{"issue":"12","key":"104_CR20","doi-asserted-by":"publisher","first-page":"3180","DOI":"10.1093\/annonc\/mds179","volume":"23","author":"S George","year":"2012","unstructured":"George S, Reichardt P, Lechner T, Li S, Cohen DP, Demetri GD (2012) Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib. Ann Oncol 23(12):3180\u20133187. doi:10.1093\/annonc\/mds179","journal-title":"Ann Oncol"},{"issue":"2","key":"104_CR21","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.eururo.2011.05.034","volume":"60","author":"DJ Gallagher","year":"2011","unstructured":"Gallagher DJ, Al-Ahmadie H, Ostrovnaya I, Gerst SR, Regazzi A, Garcia-Grossman I, Riches J, Gounder SK, Flaherty AM, Trout A, Milowsky MI, Bajorin DF (2011) Sunitinib in urothelial cancer: clinical, pharmacokinetic, and immunohistochemical study of predictors of response. Eur Urol 60(2):344\u2013349. doi:10.1016\/j.eururo.2011.05.034","journal-title":"Eur Urol"},{"issue":"7","key":"104_CR22","doi-asserted-by":"publisher","first-page":"628","DOI":"10.18632\/oncotarget.197","volume":"1","author":"DG Powe","year":"2010","unstructured":"Powe DG, Voss MJ, Zanker KS, Habashy HO, Green AR, Ellis IO, Entschladen F (2010) Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget 1(7):628\u2013638","journal-title":"Oncotarget"},{"issue":"9","key":"104_CR23","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/nrclinonc.2011.123","volume":"8","author":"DG Powe","year":"2011","unstructured":"Powe DG, Entschladen F (2011) Targeted therapies: using beta-blockers to inhibit breast cancer progression. Nat Rev Clin Oncol 8(9):511\u2013512. doi:10.1038\/nrclinonc.2011.123","journal-title":"Nat Rev Clin Oncol"},{"issue":"19","key":"104_CR24","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1200\/JCO.2010.33.4441","volume":"29","author":"A Melhem-Bertrandt","year":"2011","unstructured":"Melhem-Bertrandt A, Chavez-Macgregor M, Lei X, Brown EN, Lee RT, Meric-Bernstam F, Sood AK, Conzen SD, Hortobagyi GN, Gonzalez-Angulo AM (2011) Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol 29(19):2645\u20132652. doi:10.1200\/JCO.2010.33.4441","journal-title":"J Clin Oncol"},{"issue":"8","key":"104_CR25","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1038\/nm1447","volume":"12","author":"PH Thaker","year":"2006","unstructured":"Thaker PH, Han LY, Kamat AA, Arevalo JM, Takahashi R, Lu C, Jennings NB, Armaiz-Pena G, Bankson JA, Ravoori M, Merritt WM, Lin YG, Mangala LS, Kim TJ, Coleman RL, Landen CN, Li Y, Felix E, Sanguino AM, Newman RA, Lloyd M, Gershenson DM, Kundra V, Lopez-Berestein G, Lutgendorf SK, Cole SW, Sood AK (2006) Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med 12(8):939\u2013944","journal-title":"Nat Med"},{"issue":"19","key":"104_CR26","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","volume":"289","author":"AV Chobanian","year":"2003","unstructured":"Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ, National Heart L, Blood Institute Joint National Committee on Prevention DE, Treatment of High Blood P, National High Blood Pressure Education Program Coordinating C (2003) The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA : J Am Med Assoc 289(19):2560\u20132572. doi:10.1001\/jama.289.19.2560","journal-title":"JAMA : J Am Med Assoc"},{"key":"104_CR27","doi-asserted-by":"publisher","unstructured":"Zhang W, Li N (2011) Prevalence, risk factors, and management of prehypertension. Int J Hypertens 2011:605359. doi:10.4061\/2011\/605359","DOI":"10.4061\/2011\/605359"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-014-0104-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-014-0104-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-014-0104-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-014-0104-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T04:51:36Z","timestamp":1678510296000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-014-0104-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,26]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["104"],"URL":"https:\/\/doi.org\/10.1007\/s10637-014-0104-7","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,26]]},"assertion":[{"value":"19 February 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}